VCP Scanner
Stock Screener
Filter stocks with fundamental & technical criteria
Market Themes
Curated industry baskets & thematic leaders
Earnings Hub
Calendar, EPS surprise stats & earnings transcripts
Market News
Real-time market intelligence & AI overviews
Insider Buying
SEC Form 4 corporate insider purchases
LearnAll lessons
Candlestick Patterns44 candles, each on two real charts
Pattern GuidesThe playbooks' setups on real breakouts
GlossaryInvesting terms in plain English
MinerviniVCP SetupsTrend Template
O'NeilCup with HandleFlat BaseDouble BottomCANSLIM Leaders
QullamaggieHigh Tight FlagsFlag BreakoutsEpisodic PivotsMomentum Leaders
KellWedge PopEMA Crossback
LivermorePivotal Points
PatternsFalling Wedge & ChannelBase Breakouts
View All Playbooks...
BreakoutsScanner
FAANG & Tech
AAPL vs MSFTNVDA vs AMDGOOGL vs META
Cloud & Cyber
CRM vs NOWCRWD vs PANWSNOW vs DDOG
Consumer & Auto
TSLA vs FAMZN vs WMTNFLX vs DIS
Finance & Crypto
JPM vs BACV vs MACOIN vs MSTR
Index & ETFs
SPY vs QQQVTI vs VOOSPY vs IWM
Compare Any Stocks...
DCF ValuationCalculate intrinsic value of US stocks
Market ValuationBuffett indicator, CAPE & macro gauges
Total ReturnSee dividends + price return history
DCA CalculatorSimulate recurring buys & compounding
VisualizeInteractive multi-year financial charts
Watchlist
BreakoutsScanner
WatchlistPricing
Ctrl K
Pricing
RVMD
← Back to Screener
VCP ScannerFree US Stock Screener & Financial Analysis

Find stocks. Analyze deeply. Research with clarity.

Data updated daily

Product

  • Screener
  • Scanner
  • Themes
  • Valuation
  • Total Return
  • DCA Calculator
  • Pricing
  • News
  • Earnings

Resources

  • Market Valuation
  • Compare
  • Insider Activity
  • Methodology
  • How It Works
  • Glossary
  • Learn

Get Ideas

Get weekly market insights — free

© 2026 VCP Scanner
AboutPrivacyTermsRefund Policy
Not financial advice. Do your own research.
ScreenerBreakoutsScannerWatchlist
RVMDRevolution Medicines, Inc.
$162.69$34.6B
Overview & Tools
OverviewChart Terminal ↗Visualize
Valuation & Forecasts
Valuation ModelsEstimatesDCF Model
Price & Analyst Data
Analyst TargetsPrice History
Financial Statements
Income StatementBalance SheetCash FlowRatios & Margins
Performance
P/E HistoryRevenue HistoryEarnings HistoryDividend HistoryTotal Return
Discovery & Screens
Live BreakoutsStock ScreenerOwnership
RVMD logo

Revolution Medicines, Inc.

RVMD
NASDAQ · Oncology Biotech
$162.69
At close - Nov 17, 4:00 PM EST - USD
Market Cap$34.59B
P/E-18.7x
52W High$224.31
Volume2.51M
OverviewTerminalAnalysisFinancialsValuationEarningsBreakoutsOwnership
VCP Research Verdict2026Q3

Pre-Revenue Biotech Burns Cash Against Thin Recognized Revenue

Revolution Medicines reports quarterly operating losses that widened from $175.7M in 2024Q3 to $373.1M in 2026Q3, driven by R&D expense rising from $151.8M to $417.1M, which suggests the equity story depends on pipeline success rather than current earnings.

GrowthMixed
ProfitabilityNegative
ValuationReview
TechnicalsMixed
Explore valuation models
MARKET ACTION

RVMD price & volume

Price trend, volume and key moving averages

Launch Terminal
Loading chart...
Decision Checklist4 Core Signals

What matters now

The signals most likely to change the investment case.

01

Earnings momentum

2/12 Beats

EPS beat 2 of last 12 quarters

02

Valuation risk

-143% Peers

P/E is 143% below peer median

03

Market leadership

RS 91 · Leader

High momentum (Outperforming 91% of market)

04

Mixed Trend

Mixed

Price < 50DMA but > 200DMA

Next CatalystEstimated earnings · Feb 4
01

Build the investment case

Start with the evidence for owning the stock and the risks that can break the thesis.

EXECUTIVE THESIS

The Investment Case

Full Analysis
Fundamental Trajectory

Revenue was effectively zero for most of the ten-quarter window before a single $197.6M print in 2026Q3, while operating margin deteriorated to -188.9% as R&D of $417.1M dominated the cost base, suggesting cost growth has far outpaced any visible revenue base.

Analyst Consensus+55.8% target
Buy(25 analysts)
23 Buy2 Hold0 Sell

The Bull Case

Upside Catalysts

Pivotal clinical studies

Revolution Medicines plans to initiate pivotal combination studies in 2026 with zoldonrasib or elironrasib, with clinical data expected in 2025.

Strong stock performance

The stock has surged 97% year-to-date, indicating strong investor confidence in the company's potential.

Upcoming clinical data

Clinical data supporting the 2026 pivotal studies is anticipated in Q2 or Q3 2025, which could serve as a catalyst.

The Bear Case

Key Downside Risks

Market performance

Price History →

Trailing total returns as of 11/18/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC).

YTD Return
RVMD+105.88%
S&P 500 (^GSPC)+7.21%
1-Year Return
RVMD+135.31%
S&P 500 (^GSPC)+10.03%
3-Year Return
RVMD+662.73%
S&P 500 (^GSPC)+54.65%
5-Year Return
RVMD+424.98%
S&P 500 (^GSPC)+56.29%
02

Test the fundamentals

Check whether operating performance supports the current valuation.

VALUATION & INTRINSIC VALUE

Valuation Scenarios

Valuation Analysis
Trailing P/E
-18.7x
Forward P/E
N/A
EV/EBITDA
N/A
FCF YieldCash Flow
N/A

Valuation vs 5-Year History

Multiple Range
Metric
Current
5Y Median
Historical Range
Percentile
P/E
-18.7x
N/A
N/A
EV/EBITDA
N/A
N/A
N/A
Price/FCF
N/A
N/A
N/A
Current Multiple
5Y Median (50th %ile)

Intrinsic Value Scenarios

DCF Projection
Bear$3.23-98.0%
Base (Fair)$183.21+6.3%
Bull$4.94-97.0%
$3.23 Bear$183.21 Base$4.94 Bull
Current Market Price: $162.69
Trades at a 11.2% discount to Base DCF ($183.21)
Open DCF & Valuation Models →Chart Terminal ↗

Growth & profitability

Annual revenue & EPS trend
Revenue FY25
-
Net income FY25
-$1.13B-88.5% YoY
Free cash flow FY25
-$914M-60.9% YoY
Operating margin FY25
-
ROIC (FY25)-54.3%
Avg ROIC 5Y-38.3%
ROE (TTM)-91.9%
Piotroski Score1 / 9
Financial Statements →
03

Monitor what changed

Recent results and news deserve attention only when they alter the forward view.

OPERATING RESULTS

Recent Earnings

Earnings History
EPS Beat Rate2/12 (17%)
Revenue Beat Rate2/12 (100%)
QuarterEPS (Act vs Est)Revenue (Act vs Est)
Q4 2026Latest
Nov 4, 2026
-$1.90+19.1%
vs -$2.35
$198M+672.4%
vs $26M
Q3 2026
Aug 5, 2026
-$3.06-50.0%
vs -$2.04
—
vs $2M
Q2 2026
May 6, 2026
-$2.29-24.5%
vs -$1.84
—
vs $2M
Q1 2026
Feb 25, 2026
-$1.86-17.7%
vs -$1.58
—
vs $4M
Historical baseline: 12 quarters analyzedGAAP / Adjusted
MARKET COVERAGE

Latest News

4 Stories
Zacks Investment Research·12h ago
Revolution Medicines Wins EU Nod for Rasonque in Pancreatic Cancer

RVMD secures European Commission approval for Rasonque in metastatic pancreatic cancer, expanding its reach after a strong U.S. launch.

GlobeNewsWire·1d ago
European Commission Approves Revolution Medicines' RASONQUE® (daraxonrasib), the First Broad RAS-Targeted Medicine in Metastatic Pancreatic Cancer

REDWOOD CITY, Calif., Nov. 16, 2026 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a global, commercial-stage oncology company dedicated to discovering, developing and delivering innovative medicines for patients with RAS-addicted cancers, today announced that the European Commission (EC) has approved RASONQUE (daraxonrasib) for the treatment of adult patients with metastatic pancreatic adenocarcinoma who have received at least one prior systemic therapy.1 RASONQUE, given once daily as oral tablets, is approved for adults with metastatic pancreatic adenocarcinoma with or without an identified RAS tumor mutation.

Seeking Alpha·1d ago
Revolution Medicines, Inc. (RVMD) Presents at Jefferies Global Healthcare Conference 2026 Transcript

Revolution Medicines, Inc. (RVMD) Presents at Jefferies Global Healthcare Conference 2026 Transcript

Defense World·2d ago
Revolution Medicines, Inc. $RVMD Stock Acquired by Aberdeen Group plc

Aberdeen Group plc increased its holdings in shares of Revolution Medicines, Inc. (NASDAQ: RVMD) by 303.1% during the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 576,371 shares of the company's stock after buying an additional 433,393 shares during the quarter.

Filtered for Revolution Medicines, Inc.More Headlines
04

Compare before deciding

Benchmark RVMD against direct peers instead of judging its metrics in isolation.

Peers Comparison

Key metrics vs top competitors for Revolution Medicines, Inc. (RVMD)

Full Screener →
CompanyPriceMarket CapP/E RatioRev Growth (1Y)Net MarginROEDiv Yield
RVMD logoRVMDRevolution Medicines, Inc.Current
$162.69$34.59B-18.69—-946.82%-91.93%—
ARVN logoARVNArvinas, Inc.
$6.82$440.03M-46.94-0.3%-3.45%-2%—
BDTX logoBDTXBlack Diamond Therapeutics, Inc.
$1.44$82.51M-1.88——-43.99%—
TNGX logoTNGXTango Therapeutics, Inc.
$22.11$3.6B-18.4948.29%—-30.34%—
KYMR logoKYMRKymera Therapeutics, Inc.
$121.52$10B-34.81-16.72%-341.87%-22.39%—
AMGN logoAMGNAmgen Inc.
$457.93$247.15B26.629.92%24.12%85.59%2.06%

Compare RVMD vs Peers

Revolution Medicines, Inc. (RVMD) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.

Closest Rival

vs ARVN

Most directly comparable listed peer for RVMD.

Scale Benchmark

vs LLY

Larger-name benchmark to compare RVMD against a more recognizable public peer.

Peer Set

Compare Top 5

vs ARVN, BDTX, TNGX, KYMR

05

Keep researching

Verify the primary filings, follow material updates, and answer the remaining questions.

RVMD SEC Filings & Documents

Revolution Medicines, Inc. (RVMD) SEC filings — annual & quarterly reports (10-K, 10-Q)

8-K Announcements

6
Material company update

Aug 5, 2026·SEC

Material company update

Jun 22, 2026·SEC

Material company update

May 6, 2026·SEC

10-K Annual Reports

2
FY 2026

Feb 25, 2026·SEC

FY 2025

Feb 26, 2025·SEC

10-Q Quarterly Reports

6
FY 2026

Aug 5, 2026·SEC

FY 2026

May 6, 2026·SEC

FY 2025

Nov 5, 2025·SEC

Get notified when RVMD posts new earnings or crosses analyst targets

Free. No account needed. Unsubscribe any time.

Free. Unsubscribe any time.

RVMD Frequently Asked Questions

Revolution Medicines, Inc. (RVMD) stock FAQ — growth, dividends, profitability & financials explained

Growth & Financials
What is Revolution Medicines, Inc.'s revenue?

Revolution Medicines, Inc. (RVMD) reported $197.6M in revenue over the trailing twelve months.

Is RVMD profitable?

No. Revolution Medicines, Inc. (RVMD) reported a net loss of $1.87B over the trailing twelve months.

Dividend & Returns
What is RVMD's return on equity?

Revolution Medicines, Inc. (RVMD) had a return on equity (ROE) of -91.9% over the trailing twelve months. A negative ROE means the company lost money over the period.

What is Revolution Medicines, Inc.'s free cash flow?

Revolution Medicines, Inc. (RVMD) had negative free cash flow of $1.44B over the trailing twelve months.

What if you invested $1,000 in RVMD back in 2017?

Total return calculator · dividends reinvested · 9+ years of data

See returns →